Peptide LibraryDasiglucagon dosage in published studies and labels
These are the doses used for Dasiglucagon in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Dasiglucagon has an FDA-approved human dose for emergency use only. As Zegalogue it is a single 0.6 mg subcutaneous injection for severe hypoglycemia in adults and children with diabetes who weigh at least 20 kg, with a second 0.6 mg dose from a new device if there is no response after 15 minutes. FDA's Drugs@FDA database lists both presentations as discontinued, though the approval still stands. Every other dose on this page is research.
FDA Approved
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.6 mg as a single rescue dose; a second 0.6 mg after 15 minutes if there is no response |
| Route | Subcutaneous |
| Frequency | Single dose for an emergency, not a scheduled medicine |
| Duration studied | Single use |
| Titration | None. The labeled dose is the same for adults and for children who weigh at least 20 kg. |
| Half-life | About 30 minutes |
| Evidence level | FDA Approved |
| Last reviewed | 2026-10-30 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Zegalogue (revised June 2026)FDA-approved label · FDA prescribing information | Adults and children with diabetes who weigh at least 20 kg, for severe hypoglycemia | 0.6 mg; a second 0.6 mg after 15 minutes if there is no response | Subcutaneous, by autoinjector or prefilled syringe | Single rescue dose | — | Rapid rise in blood glucose | ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, revised 06/2026 (Drugs@FDA) |
| Pieber et al., 2021 — phase 3, adults (label Trial A)Clinical trial · Randomised, double-blind phase 3 | Adults with type 1 diabetes during controlled insulin-induced hypoglycemia (n=170) | 0.6 mg, versus placebo or 1 mg of reconstituted glucagon | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 40 on placebo and 12 with glucagon | Pieber TR et al. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021. |
| Bailey et al., 2021 — phase 3, autoinjector (label Trial B)Clinical trial · Randomised, double-blind phase 3 | Adults with type 1 diabetes during controlled hypoglycemia (n=45) | 0.6 mg by autoinjector, versus placebo | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 35 on placebo | Bailey TS et al. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial. Diabetes Obes Metab. 2021. |
| Battelino et al., 2021 — phase 3, children (label Trial C)Clinical trial · Randomised, double-blind phase 3 | Children and adolescents aged 6 to 17 with type 1 diabetes (n=42) | 0.6 mg, versus placebo or glucagon dosed per its label | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 30 on placebo and 10 with glucagon | Battelino T et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021. |
| NCT05378672 — phase 3, children under 6 (label Trial D)Clinical trial · Open-label phase 3 with posted results | Children under 6 years, above 8 kg, with type 1 diabetes (n=8) | 0.3 or 0.6 mg, one dose by prefilled syringe into the buttocks | Subcutaneous | — | — | Supported the June 2026 change to a 20 kg weight limit; results posted on the registry | NCT05378672 — A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D |
| Hövelmann et al., 2018 — dose comparisonClinical trial · Randomised, double-blind pharmacokinetic and pharmacodynamic trial | Adults with type 1 diabetes during insulin-induced hypoglycemia (n=58) | 0.1, 0.3, 0.6 or 1.0 mg, versus 0.5 or 1.0 mg of glucagon | Subcutaneous | Single dose | — | Peak level at about 35 minutes and half-life of about 0.5 hours; early glucose response similar to glucagon | Hövelmann U et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018. |
| Laugesen et al., 2023 — low-dose pen, phase 2 (not an approved use)Clinical trial · Randomised, open-label crossover phase 2 | Adults with insulin pump-treated type 1 diabetes (n=24) | 80 mcg | Subcutaneous, by pen | As needed for impending or mild hypoglycemia | 2 weeks | Faster recovery and 11% less daily carbohydrate intake than usual care | Laugesen C et al. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial. Diabetologia. 2023. |
| Nielsen et al., 2023 — hypoglycemia after gastric bypass (not an approved use)Clinical trial · Randomised, double-blind, placebo-controlled crossover trial | People with hypoglycemia after Roux-en-Y gastric bypass (n=24) | 120 mcg | Subcutaneous self-injection | As needed | 4 weeks | Time in level 1 hypoglycemia fell 33% and in level 2 fell 54% versus placebo | Nielsen CK et al. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2023. |
| Thornton et al., 2024 — congenital hyperinsulinism, phase 3 (not an approved use)Clinical trial · Open-label, randomised phase 3 | Children aged 0.6 to 10.9 years with congenital hyperinsulinism (n=32) | 10 to 70 mcg per hour | Continuous subcutaneous infusion | — | 4 weeks randomized, then 4 weeks in all patients | No significant difference on the primary endpoint; post hoc, 43% less hypoglycemia on continuous glucose monitoring | Thornton PS et al. Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children. J Clin Endocrinol Metab. 2024. |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — animal reproduction studiesPreclinical · Animal toxicology reported in the FDA label | Pregnant rats and rabbits | 2, 10 or 24 mg/kg/day in rats and 0.1, 0.3 or 1 mg/kg/day in rabbits; not convertible to a human dose | Subcutaneous | Daily during organogenesis | — | Maternal toxicity, lower fetal weight and delayed bone formation at the higher doses; fetal malformations in rabbits at 0.3 mg/kg/day and above | ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, section 8.1 (Drugs@FDA) |
Where sources disagree
- Dasiglucagon is not glucagon. It is a 29-amino-acid analog with seven substitutions that keep it stable in solution, so glucagon doses and dasiglucagon doses are not interchangeable: 0.6 mg of one was compared with 1 mg of the other.
- FDA's Drugs@FDA database lists both Zegalogue presentations as discontinued, and FDA's NDC directory gives them a marketing end date of 31 August 2027, even though FDA approved a label change in June 2026. Approval and availability are separate questions.
- The June 2026 label covers people who weigh at least 20 kg. DailyMed's copy still showed the older "aged 6 years and above" wording at this review.
- Everything below 0.6 mg, and all continuous infusion, is research. The congenital hyperinsulinism and low-dose uses are not on the label.
- In a low-dose study, nausea and vomiting were more frequent than with the same doses of commercial glucagon, which the authors thought might reflect higher potency.